Medispray Laboratories Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Medispray Laboratories Private Limited Pharmaceutical Export Portfolio Dataset — 7 Products, $16.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medispray Laboratories Private Limited — Pharmaceutical Exporter Profile (2026) | 7 Products, $16.4M Trade | TransData Nexus

Medispray Laboratories Private Limited

Indian Pharmaceutical Exporter · Respiratory Specialist · $16.4M Total Trade · DGFT Verified

Medispray Laboratories Private Limited is an Indian pharmaceutical exporter with a total trade value of $16.4M across 7 products in 2 therapeutic categories. Based on 407 verified export shipments from Indian Customs (DGFT) records, Medispray Laboratories Private Limited is the #1 Indian exporter in 2 products including Citalopram, Escitalopram. Top exports include Salbutamol ($4.9M), Citalopram ($3.9M), Escitalopram ($3.9M).

Medispray Laboratories Private Limited — Export Portfolio & Destination Treemap

Medispray Laboratories Private Limited pharmaceutical export portfolio — 7 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Medispray Laboratories Private Limited? — Company Overview & Market Position

Medispray Laboratories Private Limited, incorporated on February 21, 1992, is a private Indian pharmaceutical company headquartered in Goa. The company is registered under the Corporate Identification Number (CIN) U52311GA1992PTC002801. Its authorized share capital is ₹51,000,000, with a paid-up capital of ₹510,200. The registered office is located at Plot No. 344/345, Kundaim Industrial Estate, Kundaim, Goa 403 115.

Medispray Laboratories specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio is concentrated in two therapeutic categories: Respiratory (53.0%) and CNS & Psychiatric (47.0%). Notably, Medispray holds the number one market position in Citalopram and Escitalopram, with respective market shares of 1.5% and 2.0%. The top five products—Salbutamol, Citalopram, Escitalopram, Salmeterol, and Fluticasone—account for 89.3% of the company's total export value.

What Does Medispray Laboratories Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Salbutamol$4.9M

Product Portfolio — Top 7 by Export Value

Medispray Laboratories Private Limited exports 7 pharmaceutical products across 2 therapeutic categories. Market leader (#1 exporter) in 2 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Salbutamol	Respiratory	$4.9M	177	3.3%	4
2	Citalopram	CNS & Psychiatric	$3.9M	77	1.5%	1
3	Escitalopram	CNS & Psychiatric	$3.9M	77	2.0%	1
4	Salmeterol	Respiratory	$1.1M	22	1.5%	3
5	Fluticasone	Respiratory	$950.0K	19	0.5%	3
6	Formoterol	Respiratory	$950.0K	19	1.3%	5
7	Budesonide	Respiratory	$800.0K	16	0.3%	7

Medispray Laboratories Private Limited exports 7 pharmaceutical products across 2 therapeutic categories with a total export value of $16.4M. The company is the #1 Indian exporter in 2 products: Citalopram, Escitalopram. The top category is Respiratory (53.0% of portfolio), followed by CNS & Psychiatric (47.0%), indicating a concentrated portfolio with the top 5 products accounting for 89.3% of total export value.

Medispray Laboratories Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Medispray Laboratories operates manufacturing facilities in Goa, India, specifically within the Kundaim Industrial Estate. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific production capacities are not publicly disclosed, the company's substantial export value of $16.4 million USD over 407 shipments indicates a significant manufacturing capability.

3Key Leadership

As of October 2022, Sanjay Kumar Mishra serves as the Managing Director of Medispray Laboratories Private Limited. Piyush Vadilal Salot was appointed as the Chief Financial Officer (CFO) in September 2023. Other key executives include Dinesh Ramniranjan Jain, who joined as a Director in November 2019, and Anisha Naresh Udeshi, appointed as a Director in August 2021. The company's leadership team is responsible for overseeing operations, financial management, and strategic direction.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Medispray Laboratories Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Medispray Laboratories Private Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's export data indicates a diversified product range, suggesting compliance with international regulatory standards. However, specific details regarding regulatory filings, approvals, and market access status in these regions are not publicly available. The company's focus on finished pharmaceutical formulations aligns with the stringent requirements of these markets, indicating a commitment to quality and regulatory compliance.

2Emerging Markets

Medispray Laboratories has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's export data reflects a strategic approach to penetrating these regions, likely facilitated by obtaining WHO prequalification for certain products. This prequalification enables access to international procurement programs and enhances the company's credibility in these markets. While specific details on market penetration strategies are limited, the company's product portfolio and export activities suggest a proactive approach to emerging market expansion.

3Geographic Strategy

Medispray Laboratories Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Medispray Laboratories' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's focus on finished pharmaceutical formulations suggests adherence to international quality standards, which is a prerequisite for FDA approvals. However, without publicly accessible records, a comprehensive assessment of the company's FDA status cannot be conducted.

2WHO & EU GMP

Medispray Laboratories' export data indicates a commitment to quality standards, likely including compliance with WHO Good Manufacturing Practices (GMP) and EU GMP certifications. While specific certifications are not publicly disclosed, the company's focus on finished pharmaceutical formulations aligns with the stringent requirements of these standards. Obtaining WHO prequalification for certain products further supports the company's adherence to international quality norms.

3CDSCO & Indian Regulatory

Medispray Laboratories Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Medispray Laboratories operates in a competitive landscape with several key players in the pharmaceutical industry. While specific competitors are not identified in the available data, the company's focus on respiratory and CNS & psychiatric products places it in competition with other manufacturers specializing in these therapeutic areas. The company's market leadership in Citalopram and Escitalopram indicates a strong position in the CNS segment. A detailed market share comparison and head-to-head analysis would require access to proprietary market research data.

2Key Differentiators

Medispray Laboratories' key differentiators include its concentrated product portfolio, with the top five products accounting for 89.3% of its total export value, and its market leadership in Citalopram and Escitalopram. The company's focus on finished pharmaceutical formulations aligns with global demand for quality products. Additionally, the company's expansion into emerging markets and adherence to international quality standards, such as WHO prequalification, enhance its competitive advantages.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Medispray Laboratories Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Medispray Laboratories demonstrates a strong track record in the pharmaceutical industry, with a substantial export volume of $16.4 million USD over 407 shipments. The company's focus on finished pharmaceutical formulations and its market leadership in specific products indicate reliability and consistency in product quality. While specific reliability indicators are not publicly disclosed, the company's adherence to international quality standards and regulatory compliances suggest a dependable supply chain.

2Certifications to Verify

Importers should verify the following certifications when considering Medispray Laboratories as a supplier:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulations.

WHO-GMP Certification: Verify the company's adherence to World Health Organization Good Manufacturing Practices, which can be confirmed through the WHO's official website or by contacting the company directly.

Frequently Asked Questions — Medispray Laboratories Private Limited

How many pharmaceutical products does Medispray Laboratories Private Limited export from India?

Medispray Laboratories Private Limited exports 7 pharmaceutical products across 2 therapeutic categories. The top exports are Salbutamol ($4.9M), Citalopram ($3.9M), Escitalopram ($3.9M), Salmeterol ($1.1M), Fluticasone ($950.0K). Total export value is $16.4M.

What is Medispray Laboratories Private Limited's total pharmaceutical export value?

Medispray Laboratories Private Limited's total pharmaceutical export value is $16.4M, based on 407 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Medispray Laboratories Private Limited the #1 Indian exporter?

Medispray Laboratories Private Limited is the #1 Indian exporter in 2 products: Citalopram (1.5% market share), Escitalopram (2.0% market share).

What therapeutic categories does Medispray Laboratories Private Limited cover?

Medispray Laboratories Private Limited exports across 2 therapeutic categories. The largest are Respiratory (53.0%, 5 products), CNS & Psychiatric (47.0%, 2 products).

Get Full Medispray Laboratories Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.